Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm647 In Alpha-1 Antitrypsin Deficiency
Prime Medicine, Inc. NASDAQ:PRME
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
Prime Medicine FDA clears PM647 IND
Prime Medicine said the U.S. FDA cleared its investigational new drug application for PM647 in alpha-1 antitrypsin deficiency.
PRME prime Medicine announces U.S. FDA clearance of investigational new drug application for pm577a in h1069q-mutated Wilson disease
PRME prime Medicine announces U.S. FDA clearance of investigational new drug application for pm577a in h1069q-mutated Wilson disease